Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRASAGILINE MESYLATE (rasagiline) by Molecular Devices is 12. Approved for parkinson's disease (). First approved in 2025.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline on blood pressure when it is administered with increasing doses of tyramine…
Worked on RASAGILINE MESYLATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
Ambulosono Rasagiline Musical Walking Study
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo